TURKish Acute Myocardial Infarction Registry
TURKMI
1 other identifier
observational
1,930
1 country
1
Brief Summary
There is no up-to-date information regarding presentation, management and clinical course of patients with acute myocardial infarction (MI) in Turkey. TURKMI registry is designed to provide insight to the characteristics, management from symptom onset to the hospital discharge and outcome of patients with acute MI in Turkey.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Nov 2018
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
November 1, 2018
CompletedFirst Submitted
Initial submission to the registry
January 22, 2020
CompletedFirst Posted
Study publicly available on registry
January 27, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2023
CompletedFebruary 5, 2020
January 1, 2020
4.1 years
January 22, 2020
January 31, 2020
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Number of participants died
all cause of death including cardiovascular death
from enrollment till to 2 years follow up
Secondary Outcomes (1)
Number of participants developed cardiovascular morbidity
from enrollment till to 2 years follow up
Interventions
no intervention
Eligibility Criteria
The screened population will consist of all consecutive patients presenting with suspected acute MI in the participating hospitals. Men and women aged ≥18 years will be enrolled if they fulfil the following inclusion criteria; 1. having hospitalized within 48 hours of onset of symptoms of the index event 2. had a final (discharge) diagnosis of acute MI either \[ST elevation MI (STEMI) or non ST elevation (NSTEMI)\] with positive troponin levels, and 3. having signed an Informed Consent. Patients unwilling or unable to consent will be excluded. To facilitate consecutive enrolment, all patients hospitalized at each participating site with acute MI will be recruited consecutively during the same 2 consecutive weeks (15 days).
You may qualify if:
- having hospitalized within 48 hours of onset of symptoms of the index event
- had a final (discharge) diagnosis of acute MI either \[ST elevation MI (STEMI) or non ST elevation (NSTEMI)\] with positive troponin levels, and
- having signed an Informed Consent. To facilitate consecutive enrolment, all patients hospitalized at each participating site with acute MI will be recruited consecutively during the same 2 consecutive weeks (15 days).
You may not qualify if:
- \. Patients unwilling or unable to consent will be excluded.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Turkish Society of Cardiologylead
- AstraZenecacollaborator
Study Sites (1)
Meral Kayikcioglu
Izmir, 35100, Turkey (Türkiye)
Study Officials
- STUDY DIRECTOR
MUSTAFA K EROL, prof
Istanbul Private Sisli International Kolan Hospital,
- PRINCIPAL INVESTIGATOR
MERAL KAYIKCIOGLU, prof
Ege University School of Medicine Department of Cardiology
- PRINCIPAL INVESTIGATOR
MUSTAFa KILICKAP, prof
ANKARA University School of Medicine Department of Cardiology
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 2 Years
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
January 22, 2020
First Posted
January 27, 2020
Study Start
November 1, 2018
Primary Completion
December 1, 2022
Study Completion
December 31, 2023
Last Updated
February 5, 2020
Record last verified: 2020-01
Data Sharing
- IPD Sharing
- Will not share